Design, synthesis, and biological evaluation of novel hybrid dicaffeoyltartaric/diketo acid and tetrazole-substituted l -chicoric acid analogue inhibitors of human immunodeficiency virus type 1 integrase

Journal of Medicinal Chemistry

Volumn 53, Issue 22, 2010, Pages 8161-8175

  Crosby, David C ^a   Lei, Xiangyang ^b   Gibbs, Charles G ^b   McDougall, Brenda R ^a   Robinson, W Edward ^a   Reinecke, Manfred G ^b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b TEXAS CHRISTIAN UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [5 (4 FLUOROBENZYL) 2 FURYL] 3 (1,2,4 TRIAZOL 3 YL) 1,3 PROPANEDIONE; 2 (4 CAFFEOYLAMINOPHENYL) 2 HYDROXY 4 OXO 2 BUTENOIC ACID; 2 [N (4 FLUOROBENZYL) 2 PYRROLOYL] LEVO TARTARIC ACID; 2 CAFFEOYL 3 [N (4 FLUOROBENZYL) 2 PYRROLOYL] LEVO TARTARIC ACID; 2,3 BIS [(4 FLUOROBENZYL) 2 P YRROLOYL) LEVO TARTARIC ACID; 4 (3 CAFFEOYLAMINOPHENYL) 2 HYDROXY 4 OXO 2 BUTENOIC ACID; 4 (3,4 DIHYDROXYPHENYL) 2 HYDROXY 4 OXO 2 BUTENOIC ACID; 4 (3,5 DICAFFEOYLAMINOPHENYL) 2 HYDROXY 4 OXO 2 BUTENOIC ACID; 4 (4 CAFFEOYLAMINOPHENYL) 2 HYDROXY 4 OXO 2 BUTENOIC ACID; 4 [1 (4 FLUOROBENZYL) 2 PYRROLYL] 2,4 DIOXOBUTYRIC ACID; 4 FLUOROBENZYLPYRROLOYL; 5 CITEP; 6 (3,4 DIHYDROXYPHENYL) ENE 2 HYDROXY 4 OXO 2 HEXENOIC ACID; ANTIVIRUS AGENT; BETA DIKETOACID; CATECHOL; CICHORIC ACID; DICAFFEOYLOXY 1,2 BIS (5 TETRAZOLYL) ETHANE; DICAFFEOYLTARTARIC ACID; ELVITEGRAVIR; GSK 364735; INTEGRASE; INTEGRASE INHIBITOR; LEVO CICHORIC ACID; N (4 FLUOROBENZYL) 8 HYDROXY 5 (TETRAHYDRO 2H 1,2 THIAZIN 2 YL) 1,6 NAPHTHYRIDINE 7 CARBOXAMIDE S,S DIOXIDE; OXOACID; RALTEGRAVIR; TARTARIC ACID; TETRAZOLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

ANTIVIRAL ACTIVITY; ARTICLE; CONTROLLED STUDY; CYTOTOXICITY; DRUG DESIGN; DRUG POTENCY; DRUG SCREENING; DRUG STRUCTURE; DRUG SYNTHESIS; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS 1; IC 50; NONHUMAN; PHARMACOPHORE; PROTEIN PROCESSING;

CAFFEIC ACIDS; CELL LINE; HIV INTEGRASE; HIV INTEGRASE INHIBITORS; HIV-1; HUMANS; KETO ACIDS; STRUCTURE-ACTIVITY RELATIONSHIP; SUCCINATES; TETRAZOLES; VIROLOGY;

EID: 78649516180     PISSN: 00222623     EISSN: 15204804     Source Type: Journal    
DOI: 10.1021/jm1010594     Document Type: Article

References (69)

1. Charpentier, C.; Karmochkine, M.; Laureillard, D.; Tisserand, P.; Belec, L.; Weiss, L.; Si-Mohamed, A.; Piketty, C. Drug resistance profiles for the HIV integrase gene in patients failing raltegravir salvage therapy HIV Med. 2008, 9, 765-770
2. Cooper, D. A.; Steigbigel, R. T.; Gatell, J. M.; Rockstroh, J. K.; Katlama, C.; Yeni, P.; Lazzarin, A.; Clotet, B.; Kumar, P. N.; Eron, J. E.; Schechter, M.; Markowitz, M.; Loutfy, M. R.; Lennox, J. L.; Zhao, J.; Chen, J.; Ryan, D. M.; Rhodes, R. R.; Killar, J. A.; Gilde, L. R.; Strohmaier, K. M.; Meibohm, A. R.; Miller, M. D.; Hazuda, D. J.; Nessly, M. L.; DiNubile, M. J.; Isaacs, R. D.; Teppler, H.; Nguyen, B.-Y. Subgroup and resistance analyses of raltegravir for resistant HIV-1 infection N. Engl. J. Med. 2008, 359, 355-365
3. Goethals, O.; Clayton, R.; Van Ginderen, M.; Vereycken, I.; Wagemans, E.; Geluykens, P.; Dockx, K.; Strijbos, R.; Smits, V.; Vos, A.; Meersseman, G.; Jochmans, D.; Vermeire, K.; Schols, D.; Hallenberger, S.; Hertogs, K. Resistance mutations in human immunodeficiency virus type 1 integrase selected with elvitegravir confer reduced susceptibility to a wide range of integrase inhibitors J. Virol. 2008, 82, 10366-10374
4. Malet, I.; Delelis, O.; Valantin, M.-A.; Montes, B.; Soulie, C.; Wirden, M.; Tchertanov, L.; Peytavin, G.; Reynes, J.; Mouscadet, J.-F.; Katlama, C.; Calvez, V.; Marcelin, A.-G. Mutations associated with failure of raltegravir treatment affect integrase sensitivity to the inhibitor in vitro Antimicrob. Agents Chemother. 2008, 52, 1351-1358
5. Marinello, J.; Marchand, C.; Mott, B. T.; Bain, A.; Thomas, C. J.; Pommier, Y. Comparison of raltegravir and elvitegravir on HIV-1 integrase catalytic reactions and on a series of drug-resistant integrase mutants Biochemistry 2008, 47, 9345-9354
6. Shimura, K.; Kodama, E.; Sakagami, Y.; Matsuzaki, Y.; Watanabe, W.; Yamataka, K.; Watanabe, Y.; Ohata, Y.; Doi, S.; Sato, M.; Kano, M.; Ikeda, S.; Matsuoka, M. Broad antiretroviral activity and resistance profile of the novel human immunodeficiency virus integrase inhibitor elvitegravir (JTK-303/GS-9137) J. Virol. 2008, 82, 764-774
7. Kobayashi, M.; Nakahara, K.; Seki, T.; Miki, S.; Kawauchi, S.; Suyama, A.; Wakasa-Morimoto, C.; Kodama, M.; Endoh, T.; Oosugi, E.; Matsushita, Y.; Murai, H.; Fujishita, T.; Yoshinaga, T.; Garvey, E.; Foster, S.; Underwood, M.; Johns, B.; Sato, A.; Fujiwara, T. Selection of diverse and clinically relevant integrase inhibitor-resistant human immunodeficiency virus type 1 mutants Antiviral Res. 2008, 80, 213-222
8. LaFemina, R. L.; Schneider, C. L.; Robbins, H. L.; Callahan, P. L.; LeGrow, K.; Roth, E.; Schleif, W. A.; Emini, E. A. Requirement of active human immunodeficiency virus type 1 integrase enzyme for productive infection of human T-lymphoid cells J. Virol. 1992, 66, 7414-7419
9. Robinson, W. E. HIV integrase: the next target? Infect. Med. 1998, 15, 129-137
10. Lewinski, M. K.; Bushman, F. D. Retroviral DNA integration-mechanism and consequences Adv. Genet. 2005, 55, 147-181
11. Robinson, W. E., Jr.; Cordeiro, M.; Abdel-Malek, S.; Jia, Q.; Chow, S. A.; Reinecke, M. G.; Mitchell, W. M. Dicaffeoylquinic acid inhibitors of human immunodeficiency virus integrase: inhibition of the core catalytic domain of human immunodeficiency virus integrase Mol. Pharmacol. 1996, 50, 846-855
12. McDougall, B.; King, P. J.; Wu, B. W.; Hostomsky, Z.; Reinecke, M. G.; Robinson, W. E., Jr. Dicaffeoylquinic and dicaffeoyltartaric acids are selective inhibitors of human immunodeficiency virus type 1 integrase Antimicrob. Agents Chemother. 1998, 42, 140-146
13. King, P. J.; Robinson, W. E., Jr. Resistance to the anti-human immunodeficiency virus type 1 compound l -chicoric acid results from a single mutation at amino acid 140 of integrase J. Virol. 1998, 72, 8420-8424
14. Zhu, K.; Cordeiro, M. L.; Atienza, J.; Robinson, W. E., Jr.; Chow, S. A. Irreversible inhibition of human immunodeficiency virus type 1 integrase by dicaffeoylquinic acids J. Virol. 1999, 73, 3309-3316
15. Hazuda, D. J.; Felock, P.; Witmer, M.; Wolfe, A.; Stillmock, K.; Grobler, J. A.; Espeseth, A.; Gabryelski, L.; Schleif, W.; Blau, C.; Miller, M. D. Inhibitors of strand transfer that prevent integration and inhibit HIV-1 replication in cells Science 2000, 287, 646-650
16. Robinson, W. E., Jr.; Reinecke, M. G.; Abdel-Malek, S.; Jia, Q.; Chow, S. A. Inhibitors of HIV-1 replication that inhibit HIV integrase Proc. Natl. Acad. Sci. U.S.A. 1996, 93, 6326-6331
17. Espeseth, A. S.; Felock, P.; Wolfe, A.; Witmer, M.; Grobler, J.; Anthony, N.; Egbertson, M.; Melamed, J. Y.; Young, S.; Hamill, T.; Cole, J. L.; Hazuda, D. J. HIV-1 integrase inhibitors that compete with the target DNA substrate define a unique strand transfer conformation for integrase Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 11244-11249
18. Fikkert, V.; Hombrouck, A.; van Remoortel, B.; de Maeyer, M.; Pannecouque, C.; de Clercq, E.; Debyser, Z.; Witvrouw, M. Multiple mutations in human immunodeficiency virus-1 integrase confer resistance to the clinical trial drug S-1360 AIDS (London) 2004, 18, 2019-2028
19. Hazuda, D. J.; Anthony, N. J.; Gomez, R. P.; Jolly, S. M.; Wai, J. S.; Zhuang, L.; Fisher, T. E.; Embrey, M.; Guare, J. P., Jr.; Egbertson, M. S.; Vacca, J. P.; Huff, J. R.; Felock, P. J.; Witmer, M. V.; Stillmock, K. A.; Danovich, R.; Grobler, J.; Miller, M. D.; Espeseth, A. S.; Jin, L.; Chen, I.-W.; Lin, J. H.; Kassahun, K.; Ellis, J. D.; Wong, B. K.; Xu, W.; Pearson, P. G.; Schleif, W. A.; Cortese, R.; Emini, E.; Summa, V.; Holloway, M. K.; Young, S. D. A naphthyridine carboxamide provides evidence for discordant resistance between mechanistically identical inhibitors of HIV-1 integrase Proc. Natl. Acad. Sci. U.S.A. 2004, 101, 11233-11238
20. Hombrouck, A.; Voet, A.; Van Remoortel, B.; Desadeleer, C.; De Maeyer, M.; Debyser, Z.; Witvrouw, M. Mutations in human immunodeficiency virus type 1 integrase confer resistance to the naphthyridine L-870810 and cross-resistance to the clinical trial drug GS-9137 Antimicrob. Agents Chemother. 2008, 52, 2069-2078
21. Garvey, E. P.; Johns, B. A.; Gartland, M. J.; Foster, S. A.; Miller, W. H.; Ferris, R. G.; Hazen, R. J.; Underwood, M. R.; Boros, E. E.; Thompson, J. B.; Weatherhead, J. G.; Koble, C. S.; Allen, S. H.; Schaller, L. T.; Sherrill, R. G.; Yoshinaga, T.; Kobayashi, M.; Wakasa-Morimoto, C.; Miki, S.; Nakahara, K.; Noshi, T.; Sato, A.; Fujiwara, T. The naphthyridinone GSK364735 is a novel, potent human immunodeficiency virus type 1 integrase inhibitor and antiretroviral Antimicrob. Agents Chemother. 2008, 52, 901-908
22. King, P. J.; Lee, D. J.; Reinke, R. A.; Victoria, J. G.; Beale, K.; Robinson, W. E. Human immunodeficiency virus type-1 integrase containing a glycine to serine mutation at position 140 is attenuated for catalysis and resistant to integrase inhibitors Virology 2003, 306, 147-161
23. King, P. J.; Ma, G.; Miao, W.; Jia, Q.; McDougall, B. R.; Reinecke, M. G.; Cornell, C.; Kuan, J.; Kim, T. R.; Robinson, W. E., Jr. Structure-activity relationships: analogs of the dicaffeoylquinic and dicaffeoyltartaric acids as potent inhibitors of human immunodeficiency virus type 1 integrase and replication J. Med. Chem. 1999, 42, 497-509
24. Reinke, R. A.; King, P. J.; Victoria, J. G.; McDougall, B. R.; Ma, G.; Mao, Y.; Reinecke, M. G.; Robinson, W. E., Jr. Dicaffeoyltartaric acid analogues inhibit human immunodeficiency virus type 1 (HIV-1) integrase and HIV-1 replication at nontoxic concentrations J. Med. Chem. 2002, 45, 3669-3683
25. Charvat, T. T.; Lee, D. J.; Robinson, W. E.; Chamberlin, A. R. Design, synthesis, and biological evaluation of chicoric acid analogs as inhibitors of HIV-1 integrase Bioorg. Med. Chem. 2006, 14, 4552-4567
26. Zeng, L.-F.; Jiang, X.-H.; Sanchez, T.; Zhang, H.-S.; Dayam, R.; Neamati, N.; Long, Y.-Q. Novel dimeric aryldiketo containing inhibitors of HIV-1 integrase: effects of the phenyl substituent and the linker orientation Bioorg. Med. Chem. Lett. 2008, 16, 7777-7787
27. Patil, S.; Kamath, S.; Sanchez, T.; Neamati, N.; Schinazi, R. F.; Buolamwini, J. K. Synthesis and biological evaluation of novel 5(H)-phenanthridin-6-ones, 5(H)-phenanthridin-6-one diketo acid, and polycyclic aromatic diketo acid analogs as new HIV-1 integrase inhibitors Bioorg. Med. Chem. 2007, 15, 1212-1228
28. Marchand, C.; Zhang, X.; Pais, G. C. G.; Cowansage, K.; Neamati, N.; Burke, T. R., Jr.; Pommier, Y. Structural determinants for HIV-1 integrase inhibition by β-diketo acids J. Biol. Chem. 2002, 277, 12596-12603
29. Reinke, R. A.; Lee, D. J.; McDougall, B. R.; King, P. J.; Victoria, J.; Mao, Y.; Lei, X.; Reinecke, M. G.; Robinson, W. E., Jr. l -Chicoric acid inhibits human immunodeficiency virus type 1 integration in vivo and is a noncompetitive but reversible inhibitor of HIV-1 integrase in vitro Virology 2004, 326, 203-219
30. Liljebris, C.; Larsen, S. D.; Ogg, D.; Palazuk, B. J.; Bleasdale, J. E. Investigation of potential bioisosteric replacements for the carboxyl groups of peptidomimetic inhibitors of protein tyrosine phosphatase 1B: identification of a tetrazole-containing inhibitor with cellular activity J. Med. Chem. 2002, 45, 785-1798
31. Burg, D.; Hameetman, L.; Filippov, D. V.; van der Marel, G. A.; Mulder, G. J. Inhibition of glutathione S-transferase in rat hepatocytes by a glycine-tetrazole modified S-alkyl-GSH analogue Bioorg. Med. Chem. Lett. 2002, 12, 1579-1582
32. Marco, J. A.; Carda, M.; Gonzalez, F.; Rodriguez, S.; Murga, J.; Falomir, E. Erythrulose as a chiral precursor in organic synthesis. Total syntheses of frontalin and two further chiral compounds in optically active form An. Quim. 1995, 91, 103-112
33. Baderschneider, B.; Winterhalter, P. Isolation and characterization of novel benzoates, cinnamates, flavonoids, and lignans from Riesling wine and screening for antioxidant activity J. Agric. Food Chem. 2001, 49, 2788-2798
34. Perez-Magarino, S.; Ortega-Heras, M.; Cano-Mozo, E. Optimization of a solid-phase extraction method using copolymer sorbents for isolation of phenolic compounds in red wines and quantification by HPLC J. Agric. Food Chem. 2008, 56, 11560-11570
35. Chelucci, G.; Falorni, M.; Giacomelli, G. Synthesis of (4 R,5 R)-2,2-dimethyl-4,5-bis(2-pyridyl)-1,3-dioxolane from diethyl l -(+)-tartrate Gazz. Chim. Ital. 1990, 120, 731-732
36. Stephens, C. R.; Bianco, E. J.; Pilgrim, F. J. A new reagent for dehydrating primary amides under mild conditions J. Am. Chem. Soc. 1955, 77, 1701-1702
37. Obenland, C. O.; Mangold, D. J.; Marino, M. P.; Musgrave, T. R.; Keller, R. N. Ammonium azide Inorg. Synth. 1966, 8, 53-56
38. Fischer, E.; Fischer, H. O. L. Carbomethoxy derivatives of the phenolcarboxylic acids and their use in syntheses. VIII. Derivatives of orsellinic and α-resorcylic acids Ber. Dtsch. Chem. Ges. 1913, 46, 1138-1148
39. D'Accorso, N. B.; Zuazo, B. N.; Thiel, I. M. E. Synthesis of 5-[1(R, S),2-dibenzoyloxy-1-ethyl]tetrazole and 5-[1(R, S),2-dihydroxy-1-ethyl]tetrazole Anal. Asoc. Quim. Argent. 1982, 70, 793-799
40. Horenstein, B. A.; Nakanishi, K. Synthesis of unprotected (±)-tunichrome An-1, a tunicate blood pigment J. Am. Chem. Soc. 1989, 111, 6242-6246
41. Lee, D. J.; Robinson, W. E., Jr. Preliminary mapping of a putative inhibitor-binding pocket for human immunodeficiency virus type 1 integrase inhibitors Antimicrob. Agents Chemother. 2006, 50, 134-142
42. Lee, D. J.; Robinson, W. E., Jr. Human immunodeficiency virus type 1 (HIV-1) integrase: resistance to diketo acid integrase inhibitors impairs HIV-1 replication and integration and confers cross-resistance to l -chicoric acid J. Virol. 2004, 78, 5835-5847
43. Chow, S. A. In vitro assays for activities of retroviral integrase Methods (San Diego, CA, U. S.) 1997, 12, 306-317
44. Montefiori, D. C.; Robinson, W. E. J.; Schuffman, S. S.; Mitchell, W. M. Evaluation of antiviral drugs and neutralizing antibodies to human immunodeficiency virus by a rapid and sensitive microtiter infection assay J. Clin. Microbiol. 1988, 26, 231-235
45. Maurin, C.; Bailly, F.; Mbemba, G.; Mouscadet, J. F.; Cotelle, P. Design, synthesis, and anti-integrase activity of catechol-DKA hybrids Bioorg. Med. Chem. 2006, 14, 2978-2984
46. 2+ recognition of β-diketoacid and quinoxalone derivatives bearing caffeoyl or galloyl moieties linked by arylamide as potential HIV integrase inhibitors Chin. J. Chem. 2006, 24, 1086-1094
47. Lin, Z.; Neamati, N.; Zhao, H.; Kiryu, Y.; Turpin, J. A.; Aberham, C.; Strebel, K.; Kohn, K.; Witvrouw, M.; Pannecouque, C.; Debyser, Z.; De Clercq, E.; Rice, W. G.; Pommier, Y.; Burke, T. R., Jr. Chicoric acid analogs as HIV-1 integrase inhibitors J. Med. Chem. 1999, 42, 1401-1414 (Pubitemid 29200876)
48. Grobler, J. A.; Stillmock, K.; Hu, B.; Witmer, M.; Felock, P.; Espeseth, A. S.; Wolfe, A.; Egbertson, M.; Bourgeois, M.; Melamed, J.; Wai, J. S.; Young, S.; Vacca, J.; Hazuda, D. J. Diketo acid inhibitor mechanism and HIV-1 integrase: implications for metal binding in the active site of phosphotransferase enzymes Proc. Natl. Acad. Sci. U.S.A. 2002, 99, 6661-6666
49. Sechi, M.; Derudas, M.; Dallocchio, R.; Dessi, A.; Bacchi, A.; Sannia, L.; Carta, F.; Palomba, M.; Ragab, O.; Chan, C.; Shoemaker, R.; Sei, S.; Dayam, R.; Neamati, N. Design and synthesis of novel indole β-diketo acid derivatives as HIV-1 integrase inhibitors J. Med. Chem. 2004, 47, 5298-5310 (Pubitemid 39314928)
50. Pais, G. C. G.; Zhang, X.; Marchand, C.; Neamati, N.; Cowansage, K.; Svarovskaia, E. S.; Pathak, V. K.; Tang, Y.; Nicklaus, M.; Pommier, Y.; Burke, T. R., Jr. Structure activity of 3-aryl-1,3-diketo-containing compounds as HIV-1 integrase inhibitors J. Med. Chem. 2002, 45, 3184-3194
51. Wai, J. S.; Egbertson, M. S.; Payne, L. S.; Fisher, T. E.; Embrey, M. W.; Tran, L. O.; Melamed, J. Y.; Langford, H. M.; Guare, J. P., Jr.; Zhuang, L.; Grey, V. E.; Vacca, J. P.; Holloway, M. K.; Naylor-Olsen, A. M.; Hazuda, D. J.; Felock, P. J.; Wolfe, A. L.; Stillmock, K. A.; Schleif, W. A.; Gabryelski, L. J.; Young, S. D. 4-Aryl-2,4-dioxobutanoic acid inhibitors of HIV-1 integrase and viral replication in cells J. Med. Chem. 2000, 43, 4923-4926
52. Lei, X.; Gibbs, C. G.; Reinecke, M. G.; Robinson, W. E. Synthesis and Biological Activity of l -Chicoric Acid Analogs as HIV-1 Integrase Inhibitors. Abstracts of Papers, 232nd National Meeting of the American Chemical Society, San Francisco, CA, Sep 10-14, 2006; American Chemical Society: Washington, DC, 2006; MEDI 251.
53. Tchertanov, L.; Mouscadet, J.-F. Target recognition by catechols and β-ketoenols: potential contribution of hydrogen bonding and Mn/Mg chelation to HIV-1 integrase inhibition J. Med. Chem. 2007, 50, 1133-1145
54. Maignan, S.; Guilloteau, J.-P.; Zhou-Liu, Q.; Clement-Mella, C.; Mikol, V. Crystal structures of the catalytic domain of HIV-1 integrase free and complexed with its metal cofactor: high level of similarity of the active site with other viral integrases J. Mol. Biol. 1998, 282, 359-368
55. Chen, J. C.-H.; Krucinski, J.; Miercke, L. J. W.; Finer-Moore, J. S.; Tang, A. H.; Leavitt, A. D.; Stroud, R. M. Crystal structure of the HIV-1 integrase catalytic core and C-terminal domains: a model for viral DNA binding Proc. Natl. Acad. Sci. U.S.A. 2000, 97, 8233-8238
56. Goldgur, Y.; Dyda, F.; Hickman, A. B.; Jenkins, T. M.; Craigie, R.; Davies, D. R. Three new structures of the core domain of HIV-1 integrase: an active site that binds magnesium Proc. Natl. Acad. Sci. U.S.A. 1998, 95, 9150-9154
57. Goldgur, Y.; Craigie, R.; Cohen, G. H.; Fujiwara, T.; Yoshinaga, T.; Fujishita, T.; Sugimoto, H.; Endo, T.; Murai, H.; Davies, D. R. Structure of the HIV-1 integrase catalytic domain complexed with an inhibitor: a platform for antiviral drug design Proc. Natl. Acad. Sci. U.S.A. 1999, 96, 13040-13043
58. Bujacz, G.; Alexandratos, J.; Wlodawer, A.; Merkel, G.; Andrake, M.; Katz, R. A.; Skalka, A. M. Binding of different divalent cations to the active site of avian sarcoma virus integrase and their effects on enzymic activity J. Biol. Chem. 1997, 272, 18161-18168
59. Kawasuji, T.; Fuji, M.; Yoshinaga, T.; Sato, A.; Fujiwara, T.; Kiyama, R. A platform for designing HIV integrase inhibitors. Part 2: A two-metal binding model as a potential mechanism of HIV integrase inhibitors Bioorg. Med. Chem. 2006, 14, 8420-8429
60. Hare, S.; Gupta, S. S.; Valkov, E.; Engelman, A.; Cherepanov, P. Retroviral intasome assembly and inhibition of DNA strand transfer Nature (London) 2010, 464, 232-236
61. Engelman, A.; Craigie, R. Efficient magnesium-dependent human immunodeficiency virus type 1 integrase activity J. Virol. 1995, 69, 5908-5911
62. Alves, C. N.; Marti, S.; Castillo, R.; Andres, J.; Moliner, V.; Tunon, I.; Silla, E. A quantum mechanics/molecular mechanics study of the protein-ligand interaction for inhibitors of HIV-1 integrase Chem.-Eur. J. 2007, 13, 7715-7724
63. Healy, E. F.; Sanders, J.; King, P. J.; Robinson, W. E. A docking study of l -chicoric acid with HIV-1 integrase J. Mol. Graphics Modell. 2009, 27, 584-589
64. Sotriffer, C. A.; Ni, H.; McCammon, J. A. Active site binding modes of HIV-1 integrase inhibitors J. Med. Chem. 2000, 43, 4109-4117
65. Barreto, G.; Madureira, D.; Capani, F.; Aon-Bertolino, L.; Saraceno, E.; Alvarez-Giraldez, L. D. The role of catechols and free radicals in benzene toxicity: an oxidative DNA damage pathway Environ. Mol. Mutagen. 2009, 50, 771-780
66. Maurin, C.; Bailly, F.; Cotelle, P. Improved preparation and structural investigation of 4-aryl-4-oxo-2-hydroxy-2-butenoic acids and methyl esters Tetrahedron 2004, 60, 6479-6486
67. Jitoe, A.; Masuda, T.; Nakatani, N. Phenylbutenoid dimers from the rhizomes of Zingiber cassumunar Phytochemistry 1993, 32, 357-363
68. Adeva, M.; Sahagun, H.; Caballero, E.; Clairac, R. P.-L. D.; Medarde, M.; Tome, F. Open Analogues of arcyriaflavin A. Synthesis through Diels-Alder reaction between maleimides and 1-aryl-3- tert -butyldimethylsiloxy-1,3- butadienes J. Org. Chem. 2000, 65, 3387-3394
69. Berend, L.; Heymann, F. Uber m -dinitroacetophenon und seine derivate J. Prakt. Chem. 1902, 173, 290-294